Four-year-old Michelle Lowry is all about learning her letters and numbers, but her parents didnt know if they could count on seeing this day.

What they thought was a ting bug bite on Michelles neck turned out to be a tumor.

After a battery of tests, doctors at Childrens Hospital Los Angeles diagnosed Michelle with a soft tissue sarcoma.

Because of the location, surgery and radiation were ruled out. Doctors used a new precise cancer panel called OncoKids to read Michelles DNA and RNA. The panel revealed Michelle would be a perfect candidate for a targeted new drug, larotrectinib.

Doctors worked fast to get Michelle in a new clinical trial.

Two months later Michelles tumor had shrunk by 60%. Two years later the tumor is undetectable.

Based on other positive outcomes like Michelles, the FDA granted accelerated approval of larotrectinib.

OncoKids is the first cancer panel designed specifically for childrens cancers and can detect genetic alterations for pediatric cancers, including leukemia, solid tumors, sarcomas and brain tumors.

Go here to read the rest:
Healthy Living: The Right Team, Timing and Treatment - 9&10 News